Oregon Health and Science University
This is an open-label, randomized feasibility trial in which patients admitted to Oregon Health \& Science University (OHSU) after a pregnancy complicated by preeclampsia who are considering a progestin-only pill contraception postpartum will be randomized to norethindrone or drospirenone for 6 weeks following hospital discharge.
In this open-label, randomized, feasibility trial, we will recruit participants admitted to OHSU after a pregnancy complicated preeclampsia (diagnosed antepartum or postpartum). All patients admitted after a birth are offered contraception as a routine part of clinical care; only prospective participants who are undecided in their birth control method or who are considering a progestin-only pill contraception will be approached for inclusion. Participants who consent for enrollment will be randomized to norethindrone or drospirenone. Prescriptions will be filled by the OHSU research pharmacy…
Inclusion Criteria: * Admission to Oregon Health \& Science University following a birth (during the same admission) * A diagnosis of preeclampsia or chronic hypertension with superimposed preeclampsia (with or without severe features) * Considering use of a progestin-only pill for postpartum contraception Exclusion Criteria: * Planned use of a contraceptive method other than a progestin-only pill * Contraindications to drospirenone or norethindrone * Inability to monitor blood pressure at home after discharge * Inability to complete follow-up surveys by email in English
1 tablet (0.35 mg) once daily, taken at the same time each day between hospital discharge following delivery until 6 weeks postpartum.
1 tablet (4 mg) once daily for 24 days, followed by 4 inactive tablets. Repeated from hospital discharge following delivery until 6 weeks postpartum.
Arctuva estimate
Verify or correct the compensation shown for this listing.